vasoactive-intestinal-peptide has been researched along with Migraine-without-Aura* in 2 studies
1 trial(s) available for vasoactive-intestinal-peptide and Migraine-without-Aura
Article | Year |
---|---|
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.
We hypothesized that intravenous infusion of the parasympathetic transmitter, vasoactive intestinal peptide (VIP), might induce migraine attacks in migraineurs. Twelve patients with migraine without aura were allocated to receive 8 pmol kg(-1) min(-1) VIP or placebo in a randomized, double-blind crossover study. Headache was scored on a verbal rating scale (VRS), mean blood flow velocity in the middle cerebral artery (V(mean MCA)) was measured by transcranial Doppler ultrasonography, and diameter of the superficial temporal artery (STA) by high-frequency ultrasound. None of the subjects reported a migraine attack after VIP infusion. VIP induced a mild immediate headache (maximum 2 on VRS) compared with placebo (P = 0.005). Three patients reported delayed headache (3-11 h after infusion) after VIP and two after placebo (P = 0.89). V(mean MCA) decreased (16.3 +/- 5.9%) and diameter of STA increased significantly after VIP (45.9 +/- 13.9%). VIP mediates a marked dilation of cranial arteries, but does not trigger migraine attacks in migraineurs. These data provide further evidence against a purely vascular origin of migraine. Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Migraine without Aura; Vasoactive Intestinal Peptide; Vasodilation; Vasodilator Agents | 2008 |
1 other study(ies) available for vasoactive-intestinal-peptide and Migraine-without-Aura
Article | Year |
---|---|
Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods.
Increasing evidence suggests that vasoactive neuropeptides such as pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide are involved in the pathophysiology of migraine in adults, but their role in pediatric migraineurs remains unclear. We prospectively investigated plasma levels of these vasoactive neuropeptides in pediatric migraine patients without aura and compared the results with those of age-matched healthy controls.. Thirty-eight children aged 6-18 years with migraine without aura and 20 age-matched control subjects were included in the study. Neuropeptides in plasma samples from the controls, and in either the ictal or interictal periods in pediatric migraine without aura, were measured using ELISA.. PACAP-38 and vasoactive intestinal peptide levels in both ictal and interictal plasma were higher in the patients with pediatric migraine without aura than in the controls (. This study demonstrates increased plasma PACAP-38 and vasoactive intestinal peptide levels, but not calcitonin gene-related peptide and substance P levels, in pediatric patients with migraine during both attack and attack-free periods. The study findings suggest that PACAP-38 and vasoactive intestinal peptide may be implicated in the pathophysiology of migraine, particularly in pediatric migraineurs. Topics: Adolescent; Calcitonin Gene-Related Peptide; Child; Humans; Migraine without Aura; Pituitary Adenylate Cyclase-Activating Polypeptide; Substance P; Vasoactive Intestinal Peptide | 2021 |